Sage Therapeutics Announces the Appointment of Barry Greene as CEO
December 16, 2020Sage Therapeutics has welcomed new CEO, Barry Greene, a world-class leader with global experience and a significant track record of success in R&D and commercialization.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–$SAGE #Sage–Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating brain disorders, today announced that, as part of the Company’s plan to accelerate growth and leverage the talents of the leaders in the brain health space, Barry Greene has been appointed chief executive officer. Mr. Greene, who most recently served as president of Alnylam Pharmaceuticals, Inc., from 2007 to September 2020, and as its chief operating officer from 2003 to 2016, will also continue as a member of Sage’s board of directors, the company said.
“Sage is taking on one of the biggest challenges we face today with the urgent and escalating need for more options to transform the lives of millions of patients with debilitating brain health disorders,” said Barry Greene, chief executive officer at Sage. “I am impressed by the groundbreaking and relentless pursuit that Jeff has spearheaded, and one that the entire organization has embraced, to bring a new way of thinking about how we can treat brain health disorders differently. Together, Jeff with his unique neuroscience expertise, and I, along with the talented team at Sage, can leverage our collective strengths in our efforts to bring new options to patients in areas that have been lacking innovation for a very long time. I look forward to being part of such a passionate and committed team as we advance Sage’s multi-franchise strategy and work to deliver on our mission to bring positive impact to the lives of many patients and their families.”
Dr. Jonas will continue to advance the Company’s mission in the new role of chief innovation officer. In this capacity, he will bring his thought leadership and the creative, innovative thinking for which Sage is known. He will remain a member of the board and will chair Sage’s Science & Technology Forum of the Board. As chief innovation officer, Jeff will focus on his well-recognized expertise — neuroscience, development, and pipeline expansion — bringing to bear in the role his creative thinking and extensive drug development experience.
“I am optimistic about what we have done to advance breakthrough science with the goal of delivering truly different approaches to treat brain health disorders. (Read more…) We always had the vision of upending the conventional wisdom of how to think about and how to treat these disorders,” said Jeff Jonas, M.D. chief innovation officer and formerly chief executive officer at Sage. “I am proud of the progress we have made on this journey — we took the company from a research organization to a fully integrated biopharmaceutical company with the first approved product for postpartum depression and one of the strongest brain health pipelines in the industry. Our ability to attract Barry’s caliber of talent as our next CEO is a testament to these efforts and he’s committed to continuing to make progress on our journey to provide groundbreaking options for people with brain health disorders. I look forward to working with Barry and the Sage team moving forward and continuing to contribute to Sage’s advancement in my new role.”
“I’ve known and worked with Barry for 20 years,” said Kevin Starr, chairman of the board at Sage. “His appointment as CEO is the result of thoughtful succession discussions with the Board, with the aim of augmenting the executive bench with a world-class leader committed to moving Sage to the next stage of growth and commercialization. Barry is ideal to lead this mission: he has a significant track record of successfully executing on R&D and commercialization strategies. He has built and grown a multiproduct company and is very familiar with Sage’s business and culture. Having Barry as CEO and Jeff as CInO strengthens Sage for its next evolution.”